heat shock protein family D (Hsp60) member 1 pseudogene 5Genealiases: HSPD1-8P · HSPDP5
Q-omics provides the consensus-scored HSPD1P5 profile across patient tissues and cancer cell-line models. HSPD1P5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, HSPD1P5 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, HSPD1P5 RNA expression shows 16,452 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, COAD, and THYM as cancer lineages where HSPD1P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSPD1P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSPD1P5 survival associations across molecular data types. HSPD1P5 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSPD1P5 RNA expression–survival associations across cancer types. High HSPD1P5 expression shows unfavorable associations in LIHC, KIRP, ACC and ESCA, but favorable associations in READ and OV. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LIHC as the clearest survival context for HSPD1P5 RNA expression.
This table summarizes HSPD1P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for HSPD1P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSPD1P5 shows higher tumor expression in COAD, STAD, LUAD, LUSC, BLCA and HNSC. The COAD box plot shows higher HSPD1P5 RNA expression in tumor versus normal tissue (log2 FC = +0.667, t-test p < 0.001).
This table shows molecular features associated with HSPD1P5 in patient tissues and cancer cell lines. In patient samples, HSPD1P5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
